Aclaris Therapeutics, Inc. (ACRS)
NASDAQ · Healthcare
Aclaris Therapeutics, Inc. EBITDA 2017–2025
Aclaris Therapeutics, Inc. annual/quarterly ebitda history and growth rate from 2017 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Aclaris Therapeutics, Inc. ebitda for the quarter ending March 31, 2026 was -22.1 M, a 23.02% increase year-over-year.
- Aclaris Therapeutics, Inc. ebitda for the twelve months ending March 31, 2026 was -88.5 M, a 2.03% increase year-over-year.
- Aclaris Therapeutics, Inc. annual ebitda for 2025 was -75.9 M, a 46.20% decrease from 2024.
- Aclaris Therapeutics, Inc. annual ebitda for 2024 was -141.1 M, a 46.25% increase from 2023.
- Aclaris Therapeutics, Inc. annual ebitda for 2023 was -96.5 M, a 8.35% increase from 2022.
- Aclaris Therapeutics, Inc. annual ebitda for 2022 was -89.1 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Aclaris Therapeutics, Inc. EBITDA — FAQ
Aclaris Therapeutics, Inc. (ACRS) ebitda over the last 9 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ACRS's ebitda history?
The chart and table above show Aclaris Therapeutics, Inc.'s ebitda by year and by quarter, including the growth rate.